Exosomes are small membrane vesicles (30-100 nm) derived from the luminal membranes of multivesicular bodies and constitutively released by fusion with the cell membrane [1] [2] [3] [4] [5] . In addition to diffusible factors, such as cytokines, growth factors and extracellular matrix molecules, exosomes mediate local and systemic cell communication through the horizontal transfer of information, such as mRNAs, microRNAs and proteins 2, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
a r t i c l e s
Exosomes are small membrane vesicles (30-100 nm) derived from the luminal membranes of multivesicular bodies and constitutively released by fusion with the cell membrane [1] [2] [3] [4] [5] . In addition to diffusible factors, such as cytokines, growth factors and extracellular matrix molecules, exosomes mediate local and systemic cell communication through the horizontal transfer of information, such as mRNAs, microRNAs and proteins 2, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
It is well recognized that bone marrow-derived cells (BMDCs) are crucial for the generation of a suitable microenvironment for the primary tumor and the development of metastasis 16 through a process called pre-metastatic niche formation 17, 18 . Although secreted factors are known contributors to BMDC recruitment to both the primary tumor and to pre-metastatic niches [18] [19] [20] [21] , the role of exosomes in this process has not been evaluated. Exosomes may have a role in the crosstalk between the primary tumor and BMDCs, leading to the homing of both cell types to sites of metastasis 7, 22, 23 .
Here we identify tumor-derived exosomes as new factors that promote metastatic niche formation by educating BMDCs toward a pro-vasculogenic and pro-metastatic phenotype through upregulation of the MET oncoprotein [24] [25] [26] [27] [28] [29] . Our data show that a specific expression pattern of Ras-related (Rab) proteins 30, 31 is associated with exosome production in melanoma. Moreover, using circulating exosomes isolated from subjects with stage 4 melanoma, we define a melanoma-specific exosome signature comprised of tyrosinaserelated protein-2 (TYRP2), very late antigen 4 (VLA-4), heat shock protein 70 (HSP70), an HSP90 isoform and the MET oncoprotein. Notably, exosomal TYRP2 predicts disease progression in subjects with stage 3 melanoma. We also show that CD45 − C-KIT low/+ TIE2 + a r t i c l e s 8 8 4 VOLUME 18 | NUMBER 6 | JUNE 2012 nature medicine circulating bone marrow progenitors from individuals with metastatic melanoma highly express MET receptor. Our study shows that the MET oncoprotein is upregulated in bone marrow progenitor cells by tumor-derived exosomes, possibly by both direct and indirect mechanisms, promoting the education, mobilization and pro-metastatic behavior of BMDCs.
RESULTS

Exosomal proteins have diagnostic and prognostic value
To determine the relevance of circulating exosome concentrations in metastatic melanoma 32, 33 , we prospectively isolated and characterized exosomes from the plasma of human subjects with different clinical stages of melanoma. We isolated exosomes (100 nm particles) from plasma using standard methods and confirmed their identity by electron microscopy (Fig. 1a) . We confirmed the presence of known exosome markers, including CD63, CD9 and major histocompatibility complex class I (MHC-I) (data not shown). Exosome number and size distribution quantified by NanoSight analysis did not differ based on clinical stage (Supplementary Fig. 1a ). In contrast, exosome protein concentrations were higher in subjects with stage 4 disease compared to all other stages and to normal controls ( Supplementary Fig. 1b) . Furthermore, we found that individuals with stage 4 disease who had protein-poor exosomes (<50 µg ml −1 ) had a survival advantage compared to those individuals with stage 4 disease who had protein-rich exosomes (>50 µg ml −1 ) (Fig. 1b) .
Exosomes from highly metastatic mouse (B16-F10) and human (SKMel-28, SK-Mel-202, SK-Mel-265 and SK-Mel-35) melanoma cell lines expressed typical exosome markers ( Supplementary Fig. 1c and data not shown). We used mass spectrometry to identify additional humanand mouse-derived melanoma exosome proteins (Supplementary Table 1 ) that helped define a potential diagnostic signature for melanoma. Compared to control subjects, the amounts of TYRP2 (a melanoma-specific protein), VLA-4 and HSP70 were increased in the exosomes of subjects with stage 4 disease (Fig. 1c,d ), whereas only TYRP2 was significantly higher (P < 0.05) in exosomes from subjects with stage 3 disease (Fig. 1c,d) . Notably, 70% of subjects with stage 4 melanoma had exosomes that contained an isoform of HSP90, which has been reported to be key in cellular transformation 34 (Fig. 1c) . In a retrospective analysis of individuals with stage 3 melanoma, we found that the amount of exosomal TYRP2 was significantly increased (P < 0.001) in individuals who eventually developed metastatic disease ( Fig. 1e and data not shown) . These data support analyzing circulating exosomes in patients to predict stage, prognosis (stage 3) and survival in subjects with metastatic disease.
Tumor exosomes alter organ tropism and metastatic potential Exosomes from the highly malignant B16-F10, SK-Mel-28 and SKMel-202 melanoma cell lines expressed higher amounts (twofold to 20-fold) of protein than exosomes from poorly metastatic (B16-F1) 35 and nonmetastatic cell lines (melan-a) (Fig. 2a) . Other less metastatic lung, breast and colon cancer cells also secreted lower amounts of exosomal proteins than B16-F10 cells (Supplementary Fig. 2a) . To analyze the tissue distribution of the exosomes, we injected fluorescently labeled B16-F10 exosomes intravenously into naive mice. We detected the injected exosomes in the blood vessels of target organs 5 min later (Fig. 2b) . Twenty-four hours after injection, we found B16-F10 exosomes in the interstitium of the lungs and in the bone marrow (Fig. 2b) , livers and spleens of the mice (organotropic sites for B16-F10 metastasis) but not in the circulation (Supplementary  Table 2 and data not shown). To analyze vascular leakiness properties in the lung, an early event in pre-metastatic niche formation 36 , we injected B16-F10 exosomes into mice, followed by injection of fluorescently labeled dextran 24 h later. The B16-F10 exosomes enhanced the lung endothelial permeability in the mice, as judged by the presence of extravasated dextran, compared to mice injected with conditioned media, control particles (Fig. 2c) or exosomes from nonmetastatic cell lines (Supplementary Fig. 2b) .
To investigate the molecular pathways affected by exosome delivery, we performed gene expression profiling of lung tissue 24 h and 48 h after injecting B16-F10 exosomes into the tail veins of mice (Supplementary Fig. 2c ). At both time points, we found approximately 130 differentially expressed genes in mice injected with B16-F10 Expression relative to GAPDH Expression relative to GAPDH Expression relative to GAPDH Expression relative to GAPDH Expression relative to GAPDH P < 0.001 P < 0.05 P < 0.01 P < 0.001 exosomes as compared to control-particle-injected mice. Many of these genes were related to extracellular matrix remodeling and inflammation, such as the genes encoding heat-shock proteins, as well as S100A8 and S100A9 (Supplementary Table 3 ), which are known effectors of pre-metastatic niche formation 37 ; we confirmed these findings by quantitative real time PCR (Supplementary Fig. 2d) . TNFA was upregulated 24 h after exosome injection ( Supplementary  Fig. 2d ), suggesting that it could be involved in early events during the metastatic process (for example, vascular permeability) 38 .
To further examine the role of tumor exosomes in primary tumor growth and metastasis, we intravenously injected mice with B16-F10-derived exosomes three times a week, starting 7 d after orthotopic injection of B16-F10mCherry cells. In contrast to the mice injected with control particles who had no evidence of micrometastatic disease, mice treated with exosomes showed lung micrometastasis at day 19 after tumor cell injection (Fig. 2d) . Primary tumor growth was only enhanced in the exosome-injected mice 24 days after tumor cell injection (Fig. 2d) . To analyze the differences between exosomes from highly compared to poorly metastatic melanomas, we injected equal and physiological concentrations of B16-F10-and B16-F1-derived exosomes intravenously (Supplementary Fig. 3a ) into mice three times a week over 28 d, then subcutaneously implanted B16-F10 cells expressing luciferase (Online Methods). The exosome treatment did not affect primary tumor growth (Fig. 2e) . However, mice injected with B16-F10 exosomes had a greater metastatic burden in the lungs (240-fold increase, as measured by luciferase intensity; Fig. 2f ) compared to mice injected with control particles or mice treated with exosomes derived from the poorly metastatic B16-F1 cells (Fig. 2f) . Furthermore, mice treated with B16-F10 exosomes developed metastasis with a greater tissue distribution, which included bone (Fig. 2f ) and brain (data not shown), compared to either control-treated mice or B16-F1-exosome treated mice. These data suggest that qualitative differences in exosome content can mediate metastatic potential and organotropism.
Tumor exosomes enhance metastasis by bone marrow education Given the key role of BMDCs in metastatic progression 17, 39 , we determined whether tumor-derived exosomes could educate BMDCs and influence metastatic progression (Fig. 3a and Online Methods). We transplanted lethally irradiated C57BL/6 mice with bone marrow from GFP-expressing mice that we had previously treated with B16-F10 exosomes (educated bone marrow) for 28 d or with synthetic exosomes or PBS (control bone marrow). After bone marrow reconstitution, we subcutaneously implanted the C57BL/6 mice with B16-F10 cells expressing mCherry. The mice transplanted with exosomeeducated bone marrow had greater primary tumor growth than the mice transplanted with control bone marrow (Fig. 3b) , indicating that pre-education of bone marrow cells with tumor exosomes was sufficient to accelerate tumor growth. The recruitment of BMDCs and tumor vascular density were enhanced by approximately 4.5-fold and threefold, respectively, in the primary tumors of mice transplanted with educated bone marrow compared with tumors of mice transplanted with control bone marrow (Fig. 3c) .
After 28 days, we found an increase in the size and number of metastases at both typical (lungs and ipsilateral lymph nodes) and atypical (contralateral lymph nodes, mesentery and brain) sites in mice transplanted with exosome-educated bone marrow as compared to mice transplanted with control bone marrow (Supplementary Table 4 ). Mice transplanted with educated bone marrow had a threefold increase in metastatic burden, larger metastatic lesions in the lung and a twofold elevation in the number of metastasis-associated BMDCs as compared to mice transplanted with control bone marrow (Fig. 3d) . Notably, BMDCs were present in metastatic (mCherry + ) and nonmetastatic regions (mCherry − ) in mice transplanted with exosome-educated bone marrow, although in the metastatic areas, the number of BMDCs per area was higher (Supplementary Fig. 3b) . Moreover, education of bone marrow cells with B16-F10 exosomes also increased primary tumor growth 1.3-fold and metastatic burden tenfold in less metastatic models such as Lewis lung carcinoma ( Supplementary Fig. 4) , showing a crucial role for bone marrow cell education by tumor exosomes in regulating tumor metastasis.
To further define the mechanisms of the exosome education of BMDCs, we analyzed the effect of B16-F10 and B16-F1 exosomes on bone marrow progenitor cells. Twenty-eight days of B16-F10 exosome treatment in mice led to a twofold increase in the frequency of pro-angiogenic c-Kit + Tie2 + cells in the bone marrow, whereas c-Kit + Sca1 + hematopoietic stem cells were not affected by exosome treatment (Fig. 3e) . Exosome education did not affect other bone marrow-derived cell populations, including CD11b + , CD11b + Gr1 + , F4/80 + or VEGFR1 + cells (data not shown), which are commonly mobilized by growth factors and chemokines 18, 21, 37 .
Transfer of exosomal MET to bone marrow progenitors Exosomes are known to promote the horizontal transfer of molecules to recipient cells 8, 13, 40 . Given the differential effects of B16-F1 compared to B16-F10 exosomes on metastatic potential together with previous studies suggesting differences in B16-F10 and B16-F1 membranederived vesicles 41 , we identified proteins that were highly expressed in the B16-F10 exosomes but that were present in much lower amounts in the B16-F1 exosomes by proteomic profiling (Supplementary Table 5 ). Some candidates with known roles in tumorigenesis and metastasis include the Met oncoprotein, CD44, Hsp70 and annexin A6 (refs. 24,42) . Given the key role of MET signaling in migration, invasion, angiogenesis and bone marrow cell mobilization 24, 25, 43, 44 , we focused our functional analyses on this proto-oncogene. We hypothesized that exosomes could horizontally transfer MET from melanoma to bone marrow progenitor cells and that this transfer could be a previously unknown mechanism for promoting metastatic progression. We verified that the amounts of Met and phosphorylated Met (pMet) were greater in both B16-F10 exosomes and cells compared to B16-F1 exosomes and cells, respectively (Fig. 4a) . After 28 d of exosome education, Met expression was increased in bone marrow progenitor cells from mice injected with B16-F10 exosomes (Fig. 4b) but not in mice injected with the B16-F1 exosomes. Notably, Cd44 expression in BMDCs was not affected by treatment with either B16-F10 or B16-F1 exosomes (Fig. 4b) . These data suggest that exosome-mediated Met transfer is partially responsible for increased Met expression in bone marrow progenitor cells.
To determine the functional consequences of Met expression within exosomes, we reduced the amount of Met expression in B16-F10 tumor cells by 40% and the amount of pMet by 80% using Met shRNAs (B16-F10shMet; Supplementary Fig. 5a ). Using fluorescently labeled exosomes isolated from B16-F10, B16-F10shMet and B16-F1 cells, we found a sixfold increase in c-Kit + Met + bone marrow progenitors after treating bone marrow cells with B16-F10 exosomes as compared to treating cells with B16-F10shMet, B16-F1 exosomes or control particles ( Fig. 4c and Supplementary Fig. 5b) . Notably, exosome uptake quantified by flow cytometry was similar regardless of exosome origin and Met expression (Fig. 4c) . To determine whether B16-F10 exosomes contribute to activation of the MET pathway in BMDCs, we analyzed the phosphorylation of downstream mediators of hepatocyte growth factor (HGF)-MET signaling, such as pS6 kinase (in the mammalian target of rapamycin (mTOR) pathway) and pERK (in the mitogenactivated protein kinase (MAPK) pathway), which are known effectors of MET-mediated bone marrow progenitor cell mobilization 43, 44 . Pretreatment of bone marrow cells with B16-F10 exosomes resulted in HGF-induced S6 and ERK phosphorylation, which was not seen in nontreated bone marrow or bone marrow pretreated with B16-F1 exosomes (Supplementary Fig. 5c ). Additionally, we observed that a MET inhibitor (crizotinib) prevented HGF-induced phosphorylation of S6 kinase and ERK after treatment with B16-F10 exosomes, showing the specificity of this pathway (data not shown).
We then investigated the functional consequences of exosomemediated MET signaling in bone marrow progenitor cells. Injection with B16-F10, but not B16-F1, exosomes increased Met expression in vasculogenic (c-Kit + Tie2 + ) and hematopoietic (c-Kit + Sca1 + ) progenitors in the circulation but not in the bone marrow (Fig. 4d , highlighted in red, and Supplementary Fig. 5d ), suggesting that Met expression enhanced bone marrow cell mobilization. We made similar observations in mice transplanted with B16-F10 educated bone marrow, as described in Figure 3 (data not shown). These data suggest that Met expression enhances bone marrow cell mobilization. To determine the effects of exosome-dependent MET signaling on primary tumor growth and metastasis, we implanted B16-F10 tumor cells in mice injected with exosomes from B16-F10 and B16-F10shMet cells, as well as control particles. Although we found no differences in primary tumor growth between the groups (data not shown), mice injected with the B16-F10shMet exosomes had less lung and bone metastasis compared to mice educated with B16-F10 exosomes (Fig. 4e) . Moreover, the amounts of vasculogenic and hematopoietic precursors were lower in the bone marrow and peripheral blood of mice bearing B16-F10 tumors that were injected with B16-F10shMet exosomes compared to mice treated with B16-F10 exosomes (data not shown).
To determine the clinical relevance of our findings, we analyzed the amounts of MET and pMET in circulating exosomes isolated from subjects with stage 3 or 4 melanoma (from the same cohort as described in Fig. 1) . We found higher amounts of total and pMET in both the individuals with stage 3 melanoma and those with stage 4 melanoma compared to normal controls (Fig. 4f) . Moreover, MET protein expression analyzed by flow cytometry was higher in both bone marrow progenitor cells (CD45 − C-KIT low/+ ) and pro-vasculogenic cells (CD45 − C-KIT +/low TIE2 + ) isolated from the blood of subjects with stage 4 disease compared to cells isolated from control subjects with stage 1-3 disease (Fig. 4g and Supplementary Fig. 5e ). Our data suggest that MET expression in circulating exosomes and bone marrow progenitor cells could be new predictors or early markers of metastatic disease.
Rab27a regulates exosome production and metastasis As Ras-related RAB proteins control exosome biogenesis 30 , we analyzed the expression of RAB genes (RAB1A, RAB5A, RAB5B, RAB7, RAB27A and RAB27B) using a panel of 39 human-derived melanoma cell lines. Notably, those cell lines producing high concentrations of exosomes also had high expression of RAB27A, RAB5B and RAB7 mRNA relative to those cell lines producing lower concentrations of exosomes (Fig. 5a,b) . Given the key role of RAB27 in exosome release 31 , we reasoned that inactivating this gene would reduce exosome production. We selected the Rab27a isoform for knockdown, as it was selectively expressed in melanoma-derived cell lines (Fig. 5a and data not shown) . We effectively reduced the expression of Rab27a in B16-F10 and SK-Mel-28 cells (Fig. 5c) , which resulted in a 50% decrease in exosome secretion ( Fig. 5d and Supplementary Fig. 6a) , showing a role for Rab27a in exosome production by melanoma cells. Although we found no marked differences in total protein, protein content, exosome-specific markers or the amount of Met and pMet between the control and RAb27a knockdown cells and exosomes (Supplementary Fig. 6b,c) , we did find a decrease in the secretion of placental growth factor 2 (PlGF-2), platelet-derived growth factor A chain homodimer (PDGF-AA) and osteopontin as a consequence of reducing the expression of Rab27a (Fig. 5e) . Notably, Rab27a knockdown in B16-F10 and SK-Mel-28 cells reduced primary tumor growth, lung colonization and metastasis (Fig. 5f ), which were associated with a decrease in the number of BMDCs recruited to these sites ( Fig. 5g and Supplementary Fig. 6d ). Consistent with our in vitro results (Supplementary Fig. 6a ), the concentrations of circulating tumor-derived exosomes in mice bearing Rab27a knockdown tumors were reduced by 40-50 % (data not shown) and were therefore insufficient to educate and mobilize BMDCs.
By injecting increasing amounts of exosomes isolated from either B16-F10shScramble (B16-F10 cells plus scramble shRNA) or B16-F10shRab27a (B16-F10 cells plus Rab27a shRNA) cell lines in mice followed by flank injection of tumor cells, we observed a dose-dependent increase in metastatic burden (Supplementary Fig. 7a,b) . These data suggest that quantitative differences in exosome production can alter metastatic potential. Because overexpression of Rab27a in the B16-F1, LLC and B16-F10 cell lines led to cell death (data not shown), we were unable to determine the sufficiency of Rab27a in exosome production and modulating metastasis. Collectively, these data suggest that Rab27a knockdown in melanoma models reduces exosome production and circulating exosome concentrations, thus preventing the recruitment of the BMDCs that are necessary for metastatic progression.
DISCUSSION
Accumulating evidence indicates that exosomes are mediators of metastasis 3, 11, 13, 15, 22, 23, 45, 46 . Multiple cell types, including fibroblasts, endothelial cells and bone marrow progenitor cells, contribute to the generation of metastatic microenvironments 39, 47 and may be influenced by the horizontal transfer of molecules (for example, proteins and microRNAs) by exosomes 8, 40, 48, 49 . However, the molecular and cellular mechanisms underlying this association have not been determined. Here we show that exosomes have a role in tumor progression and metastatic niche formation that is distinct from that of tumor-derived growth factors, extracellular proteins and chemokines 18, 20, 21, 37, 50, 51 . Tumor-derived exosomes promote the education and mobilization of BMDCs that support tumor vasculogenesis, invasion and metastasis. Notably, tumor-derived exosomes recruit BMDCs through upregulation of proinflammatory molecules at pre-metastatic sites. Specifically, preconditioning the bone marrow with exosomes from a highly metastatic cancer cell line (B16-F10) can increase the metastatic tumor burden and distribution in target tissues, even for tumors of different origins with a low metastatic capacity. Our work in tumor-derived exosome biology complements Paget and Ewing's theories of metastatic spread, offering an explanation of organotropic involvement in certain metastatic diseases 52, 53 .
By comparing the protein content of exosomes from highly metastatic and poorly metastatic melanoma cells, we identified MET signaling as a principal mediator of bone marrow progenitor cell education. We identified activated MET-related signaling proteins to be differentially expressed in exosomes from highly metastatic melanoma cells compared to poorly metastatic ones, which mediated provasculogenic and metastatic effects on bone marrow progenitor cells. The MET oncogene mediates cellular transformation and tumor cell proliferation, survival, motility, invasion and metastasis 26, 28, 29, 44, 54, 55 . Here we propose a previously unknown role for exosome-packaged MET in metastatic melanoma. The unique cargo of exosomes from other tumor types may educate distinct bone marrow populations, thus directly affecting metastatic propensity and outcome. The bone marrow of mice educated with the poorly metastatic B16-F1 exosomes, which lack the MET receptor, reduced (though not statistically significant) the metastatic burden and organotropism of highly metastatic B16-F10 primary tumors, suggesting that nonmetastatic exosomes may educate bone marrow to prevent metastatic disease.
The molecular mechanisms of exosome biogenesis and secretion are not well described. We found that, among the 39 melanomaderived cell lines studied, specific RAB genes involved in exosome secretion (RAB1A, RAB5B, RAB7 and RAB27A) were highly expressed in cells lines secreting high concentrations of exosomes. Reducing the expression of RAB27A, a regulator of protein trafficking and melanoma proliferation 31, 56 , decreased exosome production and the release of proangiogenic factors (PlGF-2, osteopontin and PDGF-AA) from tumor cells, hindering BMDC mobilization, tumor growth and metastasis. Our data, together with other studies showing that overexpression of RAB27A correlates with breast cancer invasiveness and metastasis 57, 58 , suggest that RAB27A should be considered as a potential therapeutic target in cancer.
Our human studies identified a specific melanoma signature comprised of TYRP2, VLA-4, HSP70, an HSP90 isoform and MET in circulating exosomes from subjects with advanced melanoma, which npg a r t i c l e s could be used as an indicator of metastatic disease and tumor burden. We found that the coexpression of TYRP2 and MET in exosomes, as well as an increased amount of protein per exosome, predicted disease progression. In addition, we showed that MET expression is elevated in circulating pro-vasculogenic progenitors in subjects with metastatic melanoma. Thus, our work identifies quantitative and qualitative signatures, along with specific bone marrow progenitor cell populations that are mobilized, as representative hallmarks of metastatic melanoma.
Although the membrane vesicles of cancer cells have been suggested to contribute to the horizontal propagation of oncoproteins and genetic material (RNA) 5, 8, 13, 14, 40, 48 , our study is the first, to our knowledge, to show that transfer of the MET oncoprotein from tumor-derived exosomes to bone marrow progenitor cells promotes the metastatic process in vivo. Notably, we show that exosomes can alter the bone marrow in a durable manner; these results suggest that genetic or epigenetic changes could be involved in this phenomenon, as bone marrow cells retain the educated phenotype after engraftment into a new host.
Here we propose a new mechanism that controls metastatic progression through the crosstalk between tumor-derived exosomes and bone marrow progenitor cells. Collectively, our data identify exosomemediated transfer of the oncoprotein MET as a key regulator of bone marrow education and mobilization and metastatic progression.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Microarray raw data tables have been deposited in the Gene Expression Omnibus (accession number GSE36584).
Note: Supplementary information is available in the online version of the paper. a r t i c l e s nature medicine VOLUME 18 | NUMBER 6 | JUNE 2012for 5 min, washed in water and stained with saturated aqueous uranyl oxalate for 5 min. Samples were then embedded in 0.4% (w/v) uranyl acetate and 1.8% (w/v) methylcellulose and incubated on ice for 10 min. The excess liquid was then removed. The grid was dried at room temperature for 10 min and viewed at 20,000 and 50,000 magnification using an electron microscope (model 910, Carl Zeiss).
Lung leakiness experiments. Ten micrograms of total exosome protein were injected by tail vein. Conditioned media was prepared by filtering supernatant fractions of cultured B16-F10 cells through a 0.22-µm filter and ultracentifuging it at 100,000g to deplete the exosomes. One hundred microliters of cultured media were injected by tail vein injection. As controls, mice were injected with 10 µg of melan-a exosomes, PBS or synthetic 100-µm unilamellar liposomes. Twenty hours after exosome treatment, mice were injected with 2 mg of Texas Red lysinefixable dextran 70,000 MW (Invitrogen) by retro-orbital injection. One hour after dextran injection, mice were euthanized and perfused with 40 ml of PBS. Lungs were dissected and fixed in a mix of 2% PFA and 20% sucrose overnight.
Immunofluorescence. For immunofluorescence, 12 µm O.C.T. tissue sections were stained with antibodies to platelet/endothelial cell adhesion molecule 1 (CD31) (1:100) and vascular cell adhesion molecule 1 (VCAM-1) (1:100) (BD). For the vasculature analyses, each mouse was injected with 50 µg Alexa Fluor 594-conjugated Isolectin GS-IB4 (Molecular Probes) 10 min before being euthanized. GFP + and mCherry + cells were detected by their intrinsic signals. Fluorescent images were obtained using a Nikon confocal microscope (Eclipse TE2000U) and analyzed using Nikon software (EZ-C1 3.6). To determine the vessel density in the metastatic lesions, digital images of mCherry-or GFPstained sections were analyzed with ImageJ Software (NIH) by determining the pixel intensity per square micrometer.
Bone marrow progenitor cell enrichment, in vitro treatment and responses to HGF. Mice were euthanized and their bone marrow was isolated by flushing the femur and tibia with PBS using a 25G 0.5-inch needle (BD). Cell suspensions were filtered through 70-µm cell strainers (BD) before centrifugation. To enrich for progenitors, lineage positive (Lin + , meaning, CD5 + , CD45R + , CD19 + , CD11b + , Ly6G/C + and TER119 + ) bone marrow cells were immunomagnetically depleted using the EasySep Mouse Hematopoietic Progenitor Cell Enrichment Kit (Stem Cell Technologies) following the manufacturer's instructions. For in vitro bone marrow treatment with exosomes, bone marrow cells were flushed as described above and cultured in Stem Span (Stem Cell Technologies) for 16 h in the presence or absence of 20 µg ml −1 exosomes, as indicated. For the HGF analysis, bone marrow cells were then stimulated with 5 ng ml −1 HGF (Peprotech) for 4 h and collected for western blot analysis in radioimmunoprecipitation assay buffer with phosphatase inhibitors (1 mM sodium orthovanadate and 5 mM β-glycerol phosphate). For MET signaling inhibition, cells were incubated with 20 nM crizotinib (Selleck Bio) 1 h before HGF stimulation.
Quantitative real-time PCR and shRNA interference studies. Total RNA was extracted from tissues or cells using the RNeasy kit (QIAGEN) and was reverse transcribed using Superscript III reverse transcriptase (Invitrogen). Quantitative real-time PCR was performed on a 7500 Fast Real Time PCR System (Applied Biosystems) using TaqMan Universal PCR Master Mix (Applied Biosystems). Frozen tissues or cell lines were analyzed for specific gene expression by quantitative real-time PCR using predesigned TaqMan assays (specific assay numbers: mouse Met,: Mm01156972_m1, mouse Cd44: Mm01277163, human RAB27A: Hs00608302_m1, mouse Rab27a: Mm00469997_m1, S100a8: Mm00496696-g1, S100a9: Mm00656925_m1) or GFP-or mCherry-specific primers 18 using SYBR Green PCR reagents (Applied Biosystems). The relative expression was normalized to β-actin. For shRNA-mediated knockdown of Rab27a, lentiviral vectors encoding shRNAs were purchased from Thermo Fisher. The human Rab27a shRNA sense sequences used were V3LHS_300918: 5′-CCCAGTGTACTTTACCAATATA-3′ and V3LHS_300917: 5′-CAG GGAAGACCAGTGTACTTTA-3′. The Rab27a knockdown efficiency was similar for both of the human shRNAs, however, V3LHS_300918 is shown in the figures. The sense sequence for mouse Rab27a shRNA was V3LHS_300916 5′-ACAGG AGAGGTTTCGTAGCTTA-3′, and the scramble sense sequence used was
